Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308341444> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W4308341444 abstract "Abstract Background Small-cell lung cancer (SCLC) accounts for 12–15% of lung cancers and has a limited prognosis, with approximately one-third of SCLC patients having a poor performance status (PS). Patients with extensive-stage (ES) SCLC and a poor PS have a poor prognosis. For this population, overall survival from carboplatin and etoposide treatment is 7–8 months, and treatment development is an unmet medical need. Recently, the combination of an anti-PD-L1 (a ligand for programmed cell death 1) antibody and platinum-based chemotherapy has become the standard of care for ES-SCLC patients with a good PS (PS 0–1). We hypothesized that the combination of the anti-PD-L1 antibody durvalumab with carboplatin and etoposide would be feasible and effective for such patients. Methods We initiated a multicenter phase II study of durvalumab combined with carboplatin and etoposide in previously untreated ES-SCLC patients with a poor PS (PS 2–3). Eligible patients will receive durvalumab plus carboplatin and etoposide every 3 to 4 weeks for up to 4 cycles, followed by durvalumab every 4 weeks until progression or unacceptable toxicity. The dosages of carboplatin and etoposide for the second and subsequent cycles will be adaptively determined based on the adverse events of the first cycle. A total of 56 patients (43 patients with a PS of 2 and 13 patients with a PS of 3) will be enrolled in this study, with a 24-month enrollment period and a 12-month follow-up. The primary endpoint is the tolerability of carboplatin and etoposide plus durvalumab in previously untreated ES-SCLC patients with a poor PS. The secondary endpoints are the 1-year survival rate, objective response rate, progression-free survival, overall survival, ratio of PS improvement, and safety. Discussion The results of this study are intended to establish the safety and efficacy of carboplatin and etoposide plus durvalumab in patients with ES-SCLC and a poor PS. Trial registration Japan Registry of Clinical Trials (jRCT), jRCTs031200319. Registered 21 January 2021, https://jrct.niph.go.jp/en-latest-detail/jRCTs031200319" @default.
- W4308341444 created "2022-11-11" @default.
- W4308341444 creator A5006885419 @default.
- W4308341444 creator A5029655825 @default.
- W4308341444 creator A5055984304 @default.
- W4308341444 creator A5068435121 @default.
- W4308341444 creator A5081294000 @default.
- W4308341444 date "2022-11-04" @default.
- W4308341444 modified "2023-09-30" @default.
- W4308341444 title "A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol" @default.
- W4308341444 cites W2019041562 @default.
- W4308341444 cites W2073683299 @default.
- W4308341444 cites W2123767004 @default.
- W4308341444 cites W2166418266 @default.
- W4308341444 cites W2170260373 @default.
- W4308341444 cites W2283252377 @default.
- W4308341444 cites W2889646458 @default.
- W4308341444 cites W2893960509 @default.
- W4308341444 cites W2977392388 @default.
- W4308341444 cites W2986688781 @default.
- W4308341444 cites W3006467062 @default.
- W4308341444 cites W3023823544 @default.
- W4308341444 cites W3048896255 @default.
- W4308341444 cites W2319767168 @default.
- W4308341444 doi "https://doi.org/10.1186/s12885-022-10222-1" @default.
- W4308341444 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36333680" @default.
- W4308341444 hasPublicationYear "2022" @default.
- W4308341444 type Work @default.
- W4308341444 citedByCount "1" @default.
- W4308341444 countsByYear W43083414442023 @default.
- W4308341444 crossrefType "journal-article" @default.
- W4308341444 hasAuthorship W4308341444A5006885419 @default.
- W4308341444 hasAuthorship W4308341444A5029655825 @default.
- W4308341444 hasAuthorship W4308341444A5055984304 @default.
- W4308341444 hasAuthorship W4308341444A5068435121 @default.
- W4308341444 hasAuthorship W4308341444A5081294000 @default.
- W4308341444 hasBestOaLocation W43083414441 @default.
- W4308341444 hasConcept C121608353 @default.
- W4308341444 hasConcept C126322002 @default.
- W4308341444 hasConcept C143998085 @default.
- W4308341444 hasConcept C197934379 @default.
- W4308341444 hasConcept C2776256026 @default.
- W4308341444 hasConcept C2776694085 @default.
- W4308341444 hasConcept C2777701055 @default.
- W4308341444 hasConcept C2777742743 @default.
- W4308341444 hasConcept C2778119113 @default.
- W4308341444 hasConcept C2778239845 @default.
- W4308341444 hasConcept C2778375690 @default.
- W4308341444 hasConcept C2780030458 @default.
- W4308341444 hasConcept C2780140570 @default.
- W4308341444 hasConcept C2781451048 @default.
- W4308341444 hasConcept C2908647359 @default.
- W4308341444 hasConcept C71924100 @default.
- W4308341444 hasConcept C99454951 @default.
- W4308341444 hasConceptScore W4308341444C121608353 @default.
- W4308341444 hasConceptScore W4308341444C126322002 @default.
- W4308341444 hasConceptScore W4308341444C143998085 @default.
- W4308341444 hasConceptScore W4308341444C197934379 @default.
- W4308341444 hasConceptScore W4308341444C2776256026 @default.
- W4308341444 hasConceptScore W4308341444C2776694085 @default.
- W4308341444 hasConceptScore W4308341444C2777701055 @default.
- W4308341444 hasConceptScore W4308341444C2777742743 @default.
- W4308341444 hasConceptScore W4308341444C2778119113 @default.
- W4308341444 hasConceptScore W4308341444C2778239845 @default.
- W4308341444 hasConceptScore W4308341444C2778375690 @default.
- W4308341444 hasConceptScore W4308341444C2780030458 @default.
- W4308341444 hasConceptScore W4308341444C2780140570 @default.
- W4308341444 hasConceptScore W4308341444C2781451048 @default.
- W4308341444 hasConceptScore W4308341444C2908647359 @default.
- W4308341444 hasConceptScore W4308341444C71924100 @default.
- W4308341444 hasConceptScore W4308341444C99454951 @default.
- W4308341444 hasFunder F4320307770 @default.
- W4308341444 hasIssue "1" @default.
- W4308341444 hasLocation W43083414441 @default.
- W4308341444 hasLocation W43083414442 @default.
- W4308341444 hasLocation W43083414443 @default.
- W4308341444 hasOpenAccess W4308341444 @default.
- W4308341444 hasPrimaryLocation W43083414441 @default.
- W4308341444 hasRelatedWork W2031346637 @default.
- W4308341444 hasRelatedWork W2045785673 @default.
- W4308341444 hasRelatedWork W2108334876 @default.
- W4308341444 hasRelatedWork W2120734114 @default.
- W4308341444 hasRelatedWork W2348495938 @default.
- W4308341444 hasRelatedWork W2789166760 @default.
- W4308341444 hasRelatedWork W3203270799 @default.
- W4308341444 hasRelatedWork W4308341444 @default.
- W4308341444 hasRelatedWork W1830302182 @default.
- W4308341444 hasRelatedWork W2133000900 @default.
- W4308341444 hasVolume "22" @default.
- W4308341444 isParatext "false" @default.
- W4308341444 isRetracted "false" @default.
- W4308341444 workType "article" @default.